注射用胰激肽原酶治疗糖尿病肾病高凝状态探讨  

The discussion of the treatment in diabetie nephropathy for high pour-point state with pantcreatic shocr peptule enzyme by injecting

作　　者：赵长英[1] 李小军[1] 胡琼丹[1] 张茂平[1] 

机构地区：[1]泸州医学院附属中医院肾病内科,四川泸州646000

出　　处：《吉林医学》2011年第17期3401-3403,共3页Jilin Medical Journal

摘　　要：目的:探讨注射用胰激肽原酶治疗糖尿病肾病(diabetic nephropathy,DN)的疗效及合理用法。方法:对24例糖尿病肾病患者(DN组)注射胰激肽原酶,对8例健康者(对照组)空腹分次采肘静脉血,应用Sonoclot分析仪及酶联免疫法动态检测所采静脉血标本,再对所得数据进行分析。结果:给药后4 h,DN组全部患者凝血速率(CR)值均低于给药前,给药后12 h,有9例(37.5%)低于给药前,给药后24 h仅有6例(25.0%)低于给药前。DN组玻璃珠激活的凝血时间(gbACT)与活化部分凝血激酶时间(aPrr)呈正相关,CR与纤维蛋白原(FIB)呈正相关,PF1+2与CR呈正相关,PF与血小板数(PLT)呈正相关,GMP-140与PF之间无相关。结论:注射用胰激肽原酶改善糖尿病肾病微循环障碍有确切疗效,但其有效剂量和有效给药方法还需要进一步研究。Objective To investigate the injection of pancreatic kallikrein treatment of diabetic nephropathy（diabetic nephropathy,DN） of the efficacy and reasonable usage.Methods 24 patients with diabetic nephropathy（DN group） injected after pancreatic kallikrein and 8 healthy subjects（control group） fasting blood graded elbow mining application Sonoclot analyzer and dynamic detection of enzymelinked immunosorbent assay vein adopted Blood samples were analyzed the data again.Results After administration of 4 h,DN group all blood coagulation rate（CR） were lower than before administration,after administration 12 h,9 patients（37.5%） lower than before administration,after administration of 24 h only 6 cases（25.0%） lower than premedication.DN group of glass beads activated clotting time（gbACT） and activated partial thromboplastin time（aPrr） was positively correlated,CR and fibrinogen（FIB） was positively correlated,PF1＋2 with CR was positively correlated,PF and platelet count（PLT） was positively related,GMP.No correlation between the 140 and PF.Conclusion The injection of pancreatic kallikrein microcirculation in diabetic nephropathy there is a genuine effect,but the effective dose and effective drug delivery method also needs further study.

关 键 词：注射用胰激肽原酶 糖尿病肾病 SONOCLOT分析仪 酶联免疫法 

分 类 号：R587.2[医药卫生—内分泌]